HOME
LUPIN FOUNDATION
CAREERS Careers Overview Life at Lupin Campus Connect Learning & Development Current Openings P.L.E.D.G.E.
CONTACT US Contact Us Global Offices Partner With Us Lupin for Suppliers GST Information
 
2019 ▼
2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002

Lupin receives tentative U.S. FDA approval for Mirabegron ER Tablets

June 27, 2019

Appointment of Mr. Sunil Makharia as interim Chief Financial Officer and Key Managerial Personnel

June 11, 2019

Japan’s PMDA completes inspection of Lupin’s Mandideep facility (Unit-2)

June 04, 2019

Lupin wins Packaging Award for its patient awareness initiative ‘Lupin Sahayak’

May 30, 2019

Lupin wins India Packaging Award for ‘Corcal Bone & Beauty’

May 29, 2019

Lupin launches Budesonide Inhalation Suspension

May 22, 2019

U.S. FDA completes inspection of Lupin’s Aurangabad facility

May 15, 2019

Fiscal year 2019 Results

May 15, 2019

Lupin receives EIR for Pharmacovigilance inspection from the U.S. FDA

May 14, 2019

Lupin launches Clobazam Tablets

May 10, 2019

Lupin and Aptissen announce exclusive distribution agreement of Synolis VA for Canada

May 9, 2019

Lupin receives tentative U.S. FDA approval for Fosaprepitant for Injection

May 7, 2019

Lupin in alliance with Natco receives FDA approval for Bosentan Tablets

April 30, 2019

Notice of Board Meeting

April 26, 2019

Lupin receives FDA approval for Fluoxetine Tablets USP

April 16, 2019

Lupin launches Testosterone Gel

April 12, 2019

Lupin receives FDA approval for Testosterone Gel

April 11, 2019

Lupin launches Fluoxetine Tablets USP

April 10, 2019

Lupin Bioresearch Centre completes fifth successful U.S. FDA inspection

April 03, 2019

Lupin’s Pithampur Unit-3 (Indore) receives EIR from U.S. FDA

April 02, 2019

Lupin launches Tadalafil Tablets USP

April 1, 2019

Letter sent to the Exchanges regarding the resignation of Dr Vijay Kelkar from the directorship of the Company.

April 1, 2019

Lupin appoints Ms. Christine Mundkur as an Independent Director

April 1, 2019

Lupin launches Fluocinonide Ointment USP 0.05%

March 28, 2019

Lupin receives FDA approval for Tadalafil Tablets USP

March 27, 2019

Lupin’s Pune Biotech facility receives EU GMP clearance

March 27, 2019

Lupin and YL Biologics receives PMDA approval for Etanercept biosimilar in Japan

March 26, 2019

Lupin receives FDA approval for Sildenafil Tablets USP

March 25, 2019

Lupin launches generic Levothyroxine Sodium Tablets USP

March 22, 2019

Lupin receives FDA approval for Atorvastatin Calcium Tablets USP

March 7, 2019

Lupin in alliance with Natco receives FDA approval for Imatinib Mesylate Tablets

March 5, 2019

Lupin receives FDA approval for Azacitidine for Injection, 100 mg Single-Dose Vial

February 28, 2019

Lupin launches Generic Ranolazine ER Tablets in U.S.

February 28, 2019

Lupin launches generic Minocycline Hydrochloride ER Tablets USP

February 26, 2019

Lupin receives FDA approval for Methylprednisolone Tablets USP

February 25, 2019

Lupin launches Clobazam Oral Suspension, 2.5mg/mL

February 15, 2019

Lupin receives FDA approval for Fluoxetine Tablets USP

February 12, 2019

Lupin launches Tadalafil Tablets USP

February 12, 2019

U.S. FDA completes inspection of Lupin’s Goa facility

February 08, 2019

Lupin receives FDA approval for Tadalafil Tablets USP, 20 mg

February 07, 2019

Lupin Quarter III, FY2019 - Results

February 06, 2019

Lupin launches Clomipramine Hydrochloride Capsules USP

February 05, 2019

Lupin Announces Launch of Orphan Drug NaMuscla® in Germany and the UK for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders

February 01, 2019

U.S. FDA completes inspection of Lupin’s Pithampur Unit-2 (Indore) facility

January 26, 2019

Notice of 3QFY19 Earnings call

January 23, 2019

Notice of Board Meeting

January 23, 2019

Lupin receives FDA approval for Levothyroxine Sodium Tablets USP

January 21, 2019

LupinLife’s Corcal Bone & Beauty to launch at Lakme Fashion Week with an initiative to bring #Beautifullystrong real women to the ramp

January 18, 2019

Orphan Drug NaMuscla® Receives European Commission Approval for the Treatment of Myotonia in Non-Dystrophic Myotonic Disorders

January 8, 2019

Lupin Pharmaceuticals, Inc. Issues Voluntary Recall of Ceftriaxone for Injection USP, 250mg, 500mg, 1g and 2g

January 7, 2019

Lupin receives FDA approval for Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg & 120 mg

January 7, 2019

Lupin receives FDA approval for generic Temovate Ointment, 0.05%

VIEW ALL PRESS RELEASESS

Load more